Log In Get Started
Press Releases May 13, 2026 04:05 PM

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals to Present at Multiple Upcoming Investor Conferences in May and June 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
ZNTL

Zentalis Pharmaceuticals, a clinical-stage oncology company focusing on developing a first-in-class WEE1 inhibitor called azenosertib for ovarian cancer and other tumor types, announced its management team's participation in several upcoming investor conferences. These include events hosted by H.C. Wainwright, Stifel, TD Cowen, and Jefferies from May to June 2026, with live webcasts and archived presentations available on the company's website.

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
ZNTL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Zentalis Pharmaceuticals is advancing late-stage development of azenosertib, a first-in-class WEE1 inhibitor targeting ovarian cancer and multiple tumor types.
  • The management team will present at four high-profile investor conferences in May and June 2026, offering updates on clinical progress and company strategy.
  • The company emphasizes its mission to provide a non-chemotherapy, orally available treatment option that enhances patient care and outcomes in oncology.
  • Sectors impacted include biotechnology, oncology therapeutics, and investment markets focused on clinical-stage biotech innovation.

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:

  • H.C. Wainwright 4th Annual BioConnect Conference at Nasdaq, New York, NY. Fireside discussion, May 19, 2026, 2:30p.m. ET.

  • Stifel 2026 Virtual Oncology Forum, Virtual. Fireside discussion, May 20, 2026, 4:30p.m. ET.

  • TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, Virtual. Fireside discussion, May 26, 2026, 10:00a.m. ET.

  • Jefferies Global Healthcare Conference, New York, NY. Fireside discussion, June 3, 2026, 3:45p.m. ET.

Access to a live webcast of each of the H.C. Wainwright, Stifel, TD Cowen, and Jefferies events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals

ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
[email protected]


Risks

  • Clinical development risk remains as azenosertib is still investigational and late-stage trials results are pending, which could affect regulatory approval and commercial viability.
  • Market adoption risk exists if the drug does not demonstrate significant advantages over existing treatments or faces competition in ovarian cancer and tumor therapies.
  • Financial risk related to continued funding and investor sentiment around biotech stocks, especially if future clinical or business milestones are delayed or unmet.

More from Press Releases

Fervo Energy Learning Curve Continues on 3rd Generation Well Design, Boosting Drilling Rates by 143% Since Its First Cape Station Well Jul 8, 2026 Columbus Circle Capital Corp III Announces Pricing of $200,000,000 Initial Public Offering Jul 8, 2026 Mercator Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering Jul 8, 2026 Teck to Release Second Quarter 2026 Results on July 23, 2026 Jul 8, 2026 Both Leading Independent Proxy Advisors Recommend Aterian Stockholders Vote for the Asset Sale Jul 8, 2026